DXCM Forensic analysis
Price Targets (12m)
Detailed research
PART 1: TRADING EXECUTION
Trading Setup & Entry Strategy
DexCom is currently experiencing a momentum-driven recovery, trading above its 50-day SMA ($63.14), which now serves as critical support. We are seeing a BULLISH_CROSSING setup with the RSI at 62.26, indicating room for further upside before hitting overbought territory.
- >Entry Zone: $64.50 - $65.50. Do not chase the current $66.95 level. Wait for a minor retracement to test the former resistance-turned-support.
- >Stop Loss: $61.50 (HARD). Positioned just below the 10-day SMA and the 50-day trend line to mitigate risk from a trend reversal.
- >Take Profit: Target $72.00 (initial) and $76.50 (secondary). These levels align with pre-correction trading ranges.
- >Position Size: 3% of portfolio. Maintain disciplined sizing until the stock clears the 200-day SMA ($68.02) decisively.
- >Risk/Reward: 1:2.8. Strong asymmetry favored by current international expansion catalysts.
PART 2: DETAILED RESEARCH
Recent Material Events & Business Model
DexCom’s Q1 2026 performance shows robust top-line growth (15% YoY) and significant operating leverage, with operating income up 91% YoY. The pivot toward Stelo (OTC biosensor) and the new Dexcom Flex launch in Germany validates the management's focus on non-insulin dependent Type 2 diabetes as a primary growth vector.
Financial Health & Forensics
- >Revenue Quality: Strong. High portion of recurring revenue via disposable sensors.
- >Cash Position: Solid. $2.42B in cash/marketable securities provides ample buffer for growth and the $750M share repurchase program.
- >Forensic Flag: Monitor Accounts Receivable and Accrued Rebates ($1.55B). While standard for medical device distribution, these represent significant working capital drag.
Technical Analysis & Trade Timing
Technicals are currently in alignment with the fundamental growth narrative. The stock has reclaimed its 50-day SMA and is challenging the 200-day SMA. With a MACD histogram of +0.8311, the buy-side pressure is building.
Short-Term Trading Strategy (2-5 Days)
- >Timeframe: Swing Trade (2–5 Days).
- >Position Size: 3%.
- >Scaling Strategy:
- >Initial Entry (40%): $65.25.
- >Add (30%): $64.00 (retest of support).
- >Final (30%): $66.50 (breakout confirmation).
- >Take Profit: 50% at $69.50, 50% at $71.50.
- >Max Hold: 7 days. If the $61.50 level breaks, exit immediately.
Investment Recommendation
BUY. DexCom is executing on its long-term growth targets. The combination of the $1B buyback authorization and international market expansion provides a fundamental floor, while the technical breakout above the 50-day SMA suggests a continuation of the current bullish trend.
One-Liner Thesis: DexCom is successfully navigating its transition to high-growth Type 2 diabetes markets, with technical momentum now supporting a breakout toward the 200-day moving average.